Exchange: NASDAQ·Updated 05:43 PM EDT
News
all
press releases
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
BioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Gemini Space Posts Upbeat Q1 Results, Joins Figma, Sutro Biopharma And Other Big Stocks Moving Higher On Friday
Dow Jones falls 400 points, while Gemini Space Station Inc (NASDAQ: GEMI) sees 25.7% jump after strong financial results and $100M investment.read more...
Benzinga
MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of -150.00% and -13.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Truist Financial
Truist Financial raised shares of Sutro Biopharma to a "strong-buy" rating in a research report on Monday...
MarketBeat
Sutro Biopharma (NASDAQ:STRO) Sets New 1-Year High - Still a Buy?
Sutro Biopharma (NASDAQ:STRO) Sets New 52-Week High - Still a Buy...
MarketBeat
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates
Ocugen (OCGN) delivered earnings and revenue surprises of -12.57% and +27.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Sutro Biopharma (NASDAQ:STRO) Upgraded by Mizuho to "Strong-Buy" Rating
Mizuho upgraded shares of Sutro Biopharma to a "strong-buy" rating in a report on Thursday...
MarketBeat
Short Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Grows By 17.0%
Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling...
MarketBeat
Sutro Biopharma (NASDAQ:STRO) Hits New 1-Year High - What's Next?
Sutro Biopharma (NASDAQ:STRO) Reaches New 12-Month High - Still a Buy...
MarketBeat

Advertisement|Remove ads.